Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2018-07-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT JANUARI-JUNI 2018' (Interim Report January-June 2018). It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet summaries for the period. It also includes a management commentary (VD kommenterar) and detailed business updates. Since it covers a period shorter than a full fiscal year and contains substantive financial data, it is classified as an Interim/Quarterly Report. H2 2018
2018-07-12 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT JANUARY-JUNE 2018' and contains comprehensive financial statements, including a financial summary table for the group, income statements, and cash flow data for the specified period. It also includes detailed management commentary on operations and project pipelines. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2018
2018-07-12 English
Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
Regulatory Filings Classification · 1% confidence The document is a press release dated June 21, 2018, announcing the presentation of preclinical data for the drug candidate ATOR-1017 at the '3rd Annual World Preclinical Congress'. It details scientific findings regarding T cell and NK cell activation and supports a 'best-in-class profile'. This type of announcement, focusing on scientific updates, data presentation schedules, and general company news outside of mandatory financial filings (like 10-K, ER, or IR), is best classified as a general Investor Relations communication. Since it is not a formal financial report, a transcript, or a specific regulatory filing like a Director's Dealing or Major Shareholding notification, it falls under the broad category of Investor Relations material. Given the options, 'IR' (Interim / Quarterly Report) is too specific for financial results, and 'RNS' (Regulatory Filings) is a fallback. However, the content is a direct communication to investors about scientific progress, which often falls under general Investor Relations updates. Since there is no specific 'Investor Relations Update' code, and this is not a formal financial report (IR, 10-K) or a presentation deck (IP), the most appropriate classification for a scientific press release detailing ongoing development is often the general 'Regulatory Filings' (RNS) if it's a required disclosure, or sometimes 'IP' if it were the presentation itself. Given the context of a press release announcing a presentation, and lacking a specific 'Press Release' code, 'RNS' serves as the best fit for a non-financial, non-meeting related regulatory disclosure, or 'IP' if we interpret the announcement as being closely related to investor presentation material. Since it is an announcement *about* a presentation, and not the presentation itself, RNS is safer, but often these scientific updates are grouped with Investor Presentations (IP) or general news. Given the strong focus on scientific data and investor communication, and ruling out specific financial/meeting codes, I will classify this as a general regulatory/investor announcement. Since it is a press release announcing data presentation, and not a formal financial report, 'RNS' (Regulatory Filings) is the most suitable general disclosure category available.
2018-06-21 English
Alligator Biosciences ATOR-1017 ger kraftfull aktivering av både T-celler och NK-celler, viktiga för immunmedierad avdödning av tumörceller
Investor Presentation Classification · 1% confidence The document is a press release dated June 21, 2018, from Alligator Bioscience, announcing the presentation of new preclinical data for their drug candidate ATOR-1017 at the '3rd Annual World Preclinical Congress'. It details scientific findings, quotes management, and provides contact information for Investor Relations. This format—a brief announcement about scientific progress or data presentation, often released via a stock exchange wire service (implied by the Nasdaq Stockholm ticker and the structure)—is characteristic of an Investor Presentation (IP) or a general regulatory announcement. Since it is a formal announcement detailing scientific progress and strategy updates intended for investors, and it is not a full financial report (10-K, IR) or a transcript (CT), 'Investor Presentation (IP)' is the most fitting category, as these press releases often accompany or summarize the content of an investor presentation or scientific disclosure. Given the context of scientific data disclosure, IP is preferred over the generic RNS.
2018-06-21 Swedish
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics
Regulatory Filings Classification · 1% confidence The document is a press release dated May 8, 2018, announcing the presentation of new preclinical data for a bispecific immunotherapy candidate (ALG.APV-527) developed by two biotechnology companies, Alligator Bioscience and Aptevo Therapeutics. This type of announcement, detailing scientific progress, data presentation at conferences (PEGS Summit, AAI, CIMT), and future development plans (commencing clinical development in 2019), is characteristic of an Earnings Release (ER) or a general press release related to corporate/scientific updates. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Update (CAP), it best fits the 'Earnings Release' category, which often includes key operational and scientific highlights, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the focus on scientific data presentation and operational updates, ER is a strong candidate, but since it's not explicitly reporting quarterly/periodical financial results (just scientific data), and it's a joint announcement, it leans towards a general corporate update. However, in the context of financial reporting databases, scientific/operational press releases that are not explicitly about dividends, M&A, or management changes often fall under ER if they are timely updates, or RNS if they are miscellaneous. Since it is a significant update on a key asset, and these types of announcements often accompany or precede formal earnings reports, ER is plausible. If we strictly adhere to the definitions, it is a scientific/operational update. Given the options, and recognizing that many biotech updates are classified as ERs even if they lack hard numbers, I will check if it fits better elsewhere. It is not a proxy statement (PSI), management discussion (MDA), or audit report (AR). It is a press release announcing scientific progress. In many systems, this falls under ER or RNS. Given the high level of detail about the drug candidate, it is more substantial than a simple RNS notification. I will classify it as an Earnings Release (ER) as it functions as a major operational/scientific update, which often substitutes for or accompanies ERs in biotech. Revisiting the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document does not contain financial results highlights. It contains scientific data highlights. Therefore, it is a general corporate announcement. The best fit for a general, non-specific corporate/scientific press release that doesn't fit other specific categories (like M&A, DIV, DIRS) is the fallback category, RNS (Regulatory Filings/General Announcements).
2018-05-08 English
Alligator Bioscience och Aptevo Therapeutics presenterar nya prekliniska data för ALG.APV-527, en bispecifik läkemedelskandidat för immunterapi
Regulatory Filings Classification · 1% confidence The document is a press release dated May 8, 2018, announcing the presentation of new preclinical data for a drug candidate (ALG.APV-527) developed jointly by Alligator Bioscience and Aptevo Therapeutics. It details scientific findings, quotes management, and provides company background information. This type of announcement, which releases key operational and scientific updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under a general regulatory announcement or a specific investor relations category. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal presentation (IP), the most appropriate classification for a general, time-sensitive corporate update that is not covered by other specific codes (like DIRS, DIV, CAP) is the general Regulatory Filings category (RNS), as it serves as a broad announcement of material information.
2018-05-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.